Lineage Cell Therapeutics, Inc.SEC Filings
|
|
All SEC filings by Lineage Cell Therapeutics, Inc. (LCTX) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 6, 2026 | |
| 10-Q | Quarterly report | View Diff | May 12, 2026 | |
| ARS | Annual report to shareholders | Apr 29, 2026 | ||
| 10-K | Annual report | View Diff | Mar 5, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 6, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 12, 2025 | |
| 10-Q | Quarterly report | View Diff | May 13, 2025 | |
| ARS | Annual report to shareholders | Apr 29, 2025 | ||
| 10-K | Annual report | View Diff | Mar 10, 2025 | |
| 10-Q | Quarterly report | View Diff | Nov 14, 2024 |
Events
| 8-K | Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Aug 6, 2026 | ||
| 8-K | Current report | Jun 12, 2026 | ||
| 8-K | Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | May 12, 2026 | ||
| 8-K | Other Events | Mar 11, 2026 | ||
| 8-K | Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Mar 5, 2026 | ||
| 8-K | Other Events | Nov 28, 2025 | ||
| 8-K | Other Events | Nov 24, 2025 | ||
| 8-K | Other Events | Nov 12, 2025 | ||
| 8-K | Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Nov 6, 2025 | ||
| 8-K | Regulation Fd Disclosure | Aug 26, 2025 |
Registrations and Prospectuses
| S-3 | Shelf registration | View Diff | Mar 11, 2026 | |
| 424B5 | Prospectus supplement for primary offering | Mar 11, 2026 | ||
| 424B3 | Prospectus supplement | Nov 12, 2025 | ||
| S-8 | Registration of securities for employees | Aug 15, 2025 | ||
| 424B5 | Prospectus supplement for primary offering | Nov 21, 2024 | ||
| 424B5 | Prospectus supplement for primary offering | May 14, 2024 | ||
| 424B5 | Prospectus supplement for primary offering | Mar 22, 2024 | ||
| S-3 | Shelf registration | View Diff | Mar 7, 2024 | |
| 424B5 | Prospectus supplement for primary offering | Feb 6, 2024 | ||
| 424B5 | Prospectus supplement for primary offering | Feb 6, 2024 |
Proxies
| DEFA14A | Annual Meeting of Shareholders | Apr 29, 2026 | ||
| DEF 14A | Annual Meeting of Shareholders | View Diff | Apr 29, 2026 | |
| DEFA14A | Additional proxy soliciting materials | Jun 11, 2025 | ||
| DEFA14A | Additional proxy soliciting materials | Apr 29, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 29, 2025 | |
| DEF 14A | Definitive proxy | View Diff | Dec 9, 2024 | |
| PRE 14A | Preliminary proxy | View Diff | Nov 29, 2024 | |
| DEFA14A | Additional proxy soliciting materials | Apr 29, 2024 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 29, 2024 | |
| DEFA14A | Additional proxy soliciting materials | Jul 27, 2023 |
Other
| EFFECT | Notice of effectiveness | Mar 24, 2026 | ||
| CORRESP | Correspondence with SEC | Mar 19, 2026 | ||
| UPLOAD | Letter from SEC | Mar 16, 2026 | ||
| EFFECT | Notice of effectiveness | May 15, 2024 | ||
| EFFECT | Notice of effectiveness | Mar 22, 2021 | ||
| EFFECT | Notice of effectiveness | Mar 22, 2021 | ||
| CORRESP | Correspondence with SEC | Mar 17, 2021 | ||
| CORRESP | Correspondence with SEC | Mar 17, 2021 | ||
| UPLOAD | Letter from SEC | Mar 16, 2021 | ||
| UPLOAD | Letter from SEC | Mar 16, 2021 |
Ownership
| SC 13G | Blackrock, Inc. Acquires Stake in Lineage Cell Therapeutics, Inc. | Jul 29, 2026 | ||
| 4 | Bradsher Neal C | Jul 2, 2026 | ||
| 4 | Jayasuriya Anula | Jul 2, 2026 | ||
| 4 | Mulroy Michael H. | Jul 2, 2026 | ||
| 4 | Andrews Deborah J | Jul 2, 2026 | ||
| 4 | Russell Angus C. | Jul 2, 2026 | ||
| 4 | Amin Dipti | Jul 2, 2026 | ||
| 4 | Brian M Culley | Mar 12, 2026 | ||
| 4 | Brian M Culley | Mar 6, 2026 | ||
| 4 | Jill Ann Howe | Mar 6, 2026 |